The University of Colorado signs licensing agreement with Syndax Pharmaceuticals to treat lung cancer.

Syndax Pharmaceutical has signed an exclusive licensing agreement with the University of Colorado (CU) to commercialise and market a lung cancer treatment developed at the CU School of Medicine.

The treatment targets non-small-cell lung carncinoma (NSCLC), which makes up nearly 80% of lung cancers. NSCLCs are much more resistant to chemotherapy and radiation as opposed to other lung cancers.

The CU research group, working in collaboration with Syndax, have identified drug treatments that can identify and overcome NSCLC resistance.


Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?